XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a research report report published on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $123.00 price target on shares of XOMA in a research note on Tuesday.

XOMA Trading Up 0.3 %

NASDAQ:XOMA opened at $25.74 on Wednesday. XOMA has a 1 year low of $18.57 and a 1 year high of $35.00. The stock has a market cap of $303.29 million, a P/E ratio of -7.40 and a beta of 0.92. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a 50-day simple moving average of $29.20 and a 200-day simple moving average of $27.94.

Insider Buying and Selling at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

A number of institutional investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares in the last quarter. Geode Capital Management LLC increased its position in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Rhumbline Advisers raised its stake in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the last quarter. State Street Corp increased its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.